April 18, 2025

Dear Jon:

Congratulations on your promotion to Boston Scientific’s Executive Committee, effective June 30, 2025. Your leadership contribution and commitment to the long-term goals of Boston Scientific Corporation are vital to the success of Boston Scientific. Subject to your acceptance of this offer, your position title will be Executive Vice President and Chief Financial Officer, and you will become a member of Boston Scientific’s Executive Committee, an “executive officer” under the U.S. federal securities laws and an “officer” for purposes of Section 16 of the Exchange Act. You will report to Michael Mahoney, Chairman, President and CEO. This letter and your Boston Scientific Agreement Concerning Employment (ACE) summarize our understanding of the terms of your employment. We look forward to you formally accepting this offer.

COMPENSATION
Boston Scientific’s compensation programs provide our employees with significant compensation opportunities on a pay for performance basis. The objective of these programs is to recognize and reward both individual and company performance during the performance year (defined as January 1st through December 31st of each year).

Base Salary:  Your base salary for this position will be $26,923.08 currently payable bi-weekly, equivalent to $700,000 on an annualized basis. Your performance and base salary will generally be reviewed on an annual basis during the normal executive review process and approved by the Executive Compensation and Human Resources Committee of the Boston Scientific Board of Directors.  Your next performance and base salary review will be conducted during the normal executive review process, expected to commence in the first quarter of 2026.

Annual Bonus Plan:  You will continue to be eligible to participate in the Boston Scientific Corporation Annual Bonus Plan (the “Annual Bonus Plan”), subject to its terms. The Annual Bonus Plan provides employees with the opportunity for a variable financial incentive in recognition of performance each year.  Your 2025 annual target incentive will be increased from 45% to 80% of your base salary.  Your actual award will be based on your achievement of individual goals and the company's achievement of corporate performance goals.  Under the Annual Bonus Plan, generally you must be an employee on the date of payment to be eligible to earn and receive any bonus payment.

Deferred Bonus Plan: You will continue to be eligible to participate in the Boston Scientific Corporation Deferred Bonus Plan (the “Deferred Bonus Plan”), subject to its terms. This Deferred Bonus Plan allows you to save additional tax-deferred money for your future by electing to defer a portion of your annual bonus awarded under the Annual Bonus Plan. Specifically, under the Deferred Bonus Plan, on an annual basis, you can elect to defer up to 75% of the bonus awarded to you under the Annual Bonus Plan for a bonus plan year subject to the provisions of the Deferred Bonus Plan. The next bonus deferral election opportunity will be in June 2025 for the 2025 plan year (for the bonus payable in Q1 2026) and we expect a bonus deferral opportunity to be offered in each subsequent year for which you are eligible.

Promotional Equity Grant: As part of this offer, we are offering you an equity incentive award having a total value of $1,750,000 on the date of grant, which we expect to be July 1, 2025, subject to the approval of the Executive Compensation and Human Resources Committee of the Boston Scientific Board of Directors.  Your award will be made pursuant to the Amended and Restated 2011 Boston Scientific Long-Term Incentive Plan (2011 LTIP) and the relevant award agreement. The equity incentive award could be in the form of Restricted Stock Units (RSUs) or non-qualified stock options or a mix of both RSUs and non-qualified stock options, depending on your preference. Both RSUs and non-qualified options will vest 25% per year, beginning on first anniversary of date of grant, and options expire on the 10th anniversary of the grant date. The election form will be sent under separate cover shortly after you have formally accepted this offer.

Thereafter, your performance and entitlement to long term incentive compensation grants will be reviewed in the normal course, on an annual basis. The mix of stock vehicles and target value for your level will be evaluated annually by the Executive Compensation and Human Resources Committee of the Boston Scientific Board of Directors. The current program provides for an equal mix of Total Shareholder Return Performance Shares (TSR PSP), Organic Net Sales Growth Performance Shares (ONSG PSP), Restricted Stock Units (RSU’s) and Non-Qualified Stock Options.

BENEFITS
You will remain eligible to continue participation in all benefit programs for which you were previously eligible and enrolled; provided that Boston Scientific reserves the right to change and/or terminate any aspect of our benefit offerings, including employer contributions toward benefits.

Executive Physical: Effective June 30, 2025, as an Executive Committee Member, Boston Scientific will provide you with an annual executive level physical which will be coordinated through a local preferred provider. Details will be sent under separate cover.

Financial Planning: Effective June 30, 2025, as an Executive Committee Member, Boston Scientific will provide you access to financial planning services which will be coordinated through a preferred provider. Details will be sent under separate cover.

Executive Retirement Plan: Effective June 30, 2025, as an Executive Committee member, you will become eligible to participate in the Boston Scientific Corporation Executive Retirement Plan (the “Executive Retirement Plan”). As a participant, upon your “retirement” from Boston Scientific, and subject to and in accordance with the terms of the Executive Retirement Plan, you will be eligible to receive a lump sum payment of up to 36 months of your salary (less applicable withholdings). Details will be sent under separate cover.

Change in Control Agreement: Effective June 30, 2025, as an Executive Committee member, you are eligible for an executive-level Change in Control Agreement. In general, the Change in Control Agreement would entitle you to a lump sum payment of two times your base salary and assumed on-plan incentive bonus if, following a change in control of Boston Scientific, either your employment is terminated other than for “cause” or you resign for “good reason” (each as defined in the Change in Control Agreement) all subject to and in accordance with the written terms of the Change in Control Agreement. A copy of this Change in Control Agreement will be distributed to you within your first thirty days in your new role.

Boston Scientific reserves the right to amend or eliminate any of the compensation or benefit plans set forth in this offer, including without limitation the Annual Bonus Plan, the Deferred Bonus Plan, and the Executive Retirement Plan, at the sole discretion of the Boston Scientific Board of Directors or the Board’s authorized delegate, and, where required, upon notice to you prior to your retirement. The Plans in effect at the time of your retirement or other termination of employment will govern and control.

EMPLOYMENT AT WILL
You will remain an “at will” employee of Boston Scientific.  This means that you remain free to resign at any time.  Likewise, Boston Scientific will continue to have the right to terminate your employment at any time, with or without reason or notice.  Acceptance of this transfer acknowledges your continued understanding and acceptance of the “at will” nature of your employment.

This offer is contingent upon the following:

•An acceptance no later than April 23, 2025;

•Final approval of your promotion by the Boston Scientific Board of Directors; and

•A signed Agreement Concerning Employment dated on or around the date of acceptance of this offer.

Please indicate your acceptance by acknowledging below.

Jon, we would like to congratulate you on this well-deserved promotion and wish you continued success. We look forward to your acceptance of this offer. 

    Sincerely,

    Michael F. Mahoney

    Chairman, President and Chief Executive Officer

Agreed to and Accepted

by: ____________________________________ Date: _____________

MARLBOROUGH, Mass., April 23, 2025 – Boston Scientific Corporation (NYSE: BSX) today announced that Dan Brennan, executive vice president and chief financial officer, has elected to retire following nearly 30 successful years with the company. Brennan will transition out of the chief financial officer position at the end of June and is expected to remain with Boston Scientific as a senior advisor through early October 2025.

“I thank Dan for his incredible leadership and tremendous contributions to Boston Scientific,” said Mike Mahoney, chairman and chief executive officer. “Dan is an exceptional leader, financial steward and teammate. He has been a critical leader on our global team as we have transformed the trajectory of BSX financial performance over many years. In addition to helping lead our highly differentiated financial performance, Dan has been central to building our strong values and culture. Throughout his career, he has been instrumental in developing talent within the financial organization. He and his team have overseen numerous strategic internal and external investment opportunities across our businesses since he assumed CFO responsibilities in 2014.”

Jon Monson, currently senior vice president, Investor Relations will succeed Brennan as executive vice president and CFO, effective June 30, 2025, reporting to Mahoney. Brennan and Monson will work closely together to ensure a smooth transition. In this role, Jon will be a member of the Executive Committee and have responsibility for several company functions, including global controllership, global internal audit, corporate finance, treasury, corporate tax, investor relations and corporate business development. In addition to overseeing these functions, Jon will also drive capability and talent development across the company’s global Finance organization.

“Jon is a proven leader who is known for his strategic mindset, diligent and thoughtful leadership and focus on high performance and continuous innovation,” said Mahoney. “Having been with Boston Scientific for more than 25 years, he brings broad financial experience and expertise across many areas of the company which will serve him well in his new role.”

Prior to his current position leading Investor Relations, Jon held multiple roles of increasing responsibility across Boston Scientific Finance, including five years as global controller and chief accounting officer and, prior to that, four years as vice president and controller of the company's Urology business. As global controller, he played a key leadership role in navigating the company through volatile financial periods, including the 2020 pandemic. He is a certified public accountant and earned his Bachelor of Arts degree in economics and accounting from the College of the Holy Cross.

About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and connect on LinkedIn and X.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding our management transition plans, business plans and product performance, and financial performance.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical events; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property; litigation; financial market conditions; the execution and effect of our business strategy, including our cost-savings and growth initiatives; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law.  This cautionary statement is applicable to all forward-looking statements contained in this document.